Which test helps diagnose PLE by ruling out exocrine pancreatic insufficiency (EPI) and what does it assess?

Which test helps diagnose PLE by ruling out exocrine pancreatic insufficiency (EPI) and what does it assess?

• A. Texas GI panel
• B. Fecal alpha-1 proteinase inhibitor
• C. Serum amylase
• D. Urinalysis

Answer: (A)

When evaluating protein-losing enteropathy, you want to show that protein loss is occurring through the gut and you want to rule out a pancreatic cause of malabsorption. The Texas GI Panel is a comprehensive stool-based test that screens for a range of GI problems that can lead to protein loss and, importantly, includes assessment of pancreatic exocrine status. By combining markers of protein loss in the stool with information about pancreatic function, it helps distinguish protein loss due to GI mucosal disease from loss due to exocrine pancreatic insufficiency. If pancreatic function is ruled out as the culprit and stool markers indicate protein loss, that supports a diagnosis of PLE rather than EPI. Directly testing for protein loss in stool (like fecal alpha-1 proteinase inhibitor) confirms PLE but doesn’t by itself address pancreatic function, while serum amylase or urinalysis aren’t appropriate for diagnosing PLE. Hence, the Texas GI Panel is the best choice for this purpose.

When evaluating protein-losing enteropathy, you want to show that protein loss is occurring through the gut and you want to rule out a pancreatic cause of malabsorption. The Texas GI Panel is a comprehensive stool-based test that screens for a range of GI problems that can lead to protein loss and, importantly, includes assessment of pancreatic exocrine status. By combining markers of protein loss in the stool with information about pancreatic function, it helps distinguish protein loss due to GI mucosal disease from loss due to exocrine pancreatic insufficiency. If pancreatic function is ruled out as the culprit and stool markers indicate protein loss, that supports a diagnosis of PLE rather than EPI. Directly testing for protein loss in stool (like fecal alpha-1 proteinase inhibitor) confirms PLE but doesn’t by itself address pancreatic function, while serum amylase or urinalysis aren’t appropriate for diagnosing PLE. Hence, the Texas GI Panel is the best choice for this purpose.